CDK4: A Novel Therapeutic Target for Extramammary Paget’s Disease

Frontiers in Oncology

卷:11

Yoshinao Oda¹  Yumiko Kaku-Ito²  Hiroki Hashimoto²  Takamichi Ito² 

[1] Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

[2] Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

关键词: extramammary Paget’s disease;    CDK4;    cyclin D1;    prognostic factor;    targeted therapy;    CDK4/6 inhibitor;   

DOI  :  10.3389/fonc.2021.710378

来源: DOAJ

【 摘 要 】

BackgroundThe outcome of extramammary Paget’s disease (EMPD) is poor when it progresses to metastasis because of the lack of effective systemic therapies. Recently, CDK4-targeted therapy has attracted attention as a potential therapeutic target for some cancers. The aim of this study was to analyze the impact of CDK4 expression on the survival of patients with EMPD.MethodsWe retrospectively reviewed 110 patients with EMPD. We conducted immunohistochemical analysis of CDK4 and cyclin D1 expression, and assessed the association between their expression and survival.ResultsMost EMPD lesions (108/110, 98.2%) were positive for CDK4 staining and there was a positive correlation between CDK4 expression and cyclin D1 expression (r = 0.54, p < 0.001). Tumor thickness (p = 0.0003) and the presence of regional lymph node metastasis (p = 0.015) were significantly associated with high CDK4 expression. Regarding invasive EMPD, the multivariate analysis did not show the correlation between the expression of CDK4/cyclin D1 and survival outcomes (HR: 3.14, p = 0.14).ConclusionThe overexpression of CDK4 was identified as a major risk factor for disease progression. CDK4-targeted therapy could thus be a novel treatment option for unresectable EMPD.

【 授权许可】

Unknown